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Introduction: Malignant pleural mesothelioma (MPM) is a highly 
aggressive tumor with poor prognosis. one major challenge for this 
disease is the development of new, early, and highly reliable diag-
nostic markers. The aim of this study was to compare the diagnostic 
value of the chemokine chemokine (C-C motif) ligand 2 (CCL2), 
galectin-3, and the secretory leukocyte peptidase inhibitor (SLPI) 
with soluble mesothelin-related peptides (SMRP), and to evaluate 
the diagnostic performance of marker combinations.
Methods: The levels of the different markers were measured by 
enzyme-linked immunosorbent assay in pleural fluids from patients 
with MPM (n = 61), adenocarcinomas (ADCA, n = 25), or with 
benign pleural effusions (BPE, n = 15).
Results: SMRP, SLPI, and CCL2 concentrations were significantly 
higher in pleural effusions from mesothelioma patients. Conversely, 
galectin-3 levels seemed to be elevated in patients with pulmonary 
ADCA. Receiver operating characteristic curve analysis revealed 
that SMRP (area under the curve [AUC] = 0.9059), CCL2 (AUC = 
0.7912), galectin-3 (AUC = 0.7584), and SLPI (AUC = 0.7219) were 
potentially interesting biomarkers for the differentiation of MPM 
patients from those with BPE or ADCA. of interest, we showed that 
the combination of SMRP/CCL2/galectin-3 greatly improved MPM 
diagnosis (AUC = 0.9680), when compared with SMRP alone.
Conclusion: The combination of SMRP/CCL2/galectin-3 seems to 
represent a promising panel of biomarkers for the reliable diagnosis 
of MPM in pleural fluids.
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Malignant pleural mesothelioma (MPM) is a rare cancer, usually associated with asbestos exposure. As a conse-
quence of the widespread use of asbestos over the past cen-
tury, and the long latency period between asbestos exposure 
and tumor development, the worldwide incidence of MPM 
is expected to continue to rise substantially over the next 
2 decades.1,2
The diagnosis of MPM is difficult because (1) the dis-
ease may arise in patients up to 40 years after asbestos expo-
sure, (2) the clinical and imaging signs of this cancer are 
rather nonspecific and may appear late, and (3) a definitive 
diagnosis, which relies on histology, can sometimes be very 
difficult to achieve.3 It can also be difficult to distinguish 
MPM from benign pleural effusions (BPE)4 or from other 
cancers, notably adenocarcinoma (ADCA).5,6 In some cases, 
it is impossible to obtain a definitive diagnosis even after his-
tological analysis of pleural biopsies or because tumor tissue 
was not available from frail patients. To date, no single marker 
or panel of soluble (dedicated) biomarkers has been estab-
lished to obtain a clear diagnosis of MPM.7 Such a marker or 
combination of markers could be very helpful for clinicians 
for an earlier diagnosis of mesothelioma, and perhaps for the 
management of the disease (disease monitoring, prediction of 
response to treatment, and prognostic evaluation).
Soluble markers are already used routinely in the diag-
nosis and/or tumor monitoring of several types of cancer.8,9 
Soluble markers, such as osteopontin10 or soluble mesothe-
lin-related peptides (SMRP)11–15 have recently been identi-
fied as potentially useful in the evaluation of mesothelioma. 
The potential diagnostic value of SMRP in MPM was also 
supported by our study showing that SMRP results from 
an aberrant alternative messenger RNA splicing and metal-
loprotease shedding of mesothelin in mesothelioma cells.16 
However, SMRP is not secreted by some MPM, in particular 
the sarcomatoid mesothelioma subtype, which strongly limits 
its value in clinical practice. The identification and validation 
of new soluble markers are, thus, urgently needed to improve 
the noninvasive diagnosis of MPM. Because pleural effu-
sion analysis is very often the first diagnostic step in patients 
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suspected of MPM, we focused on the assessment of soluble 
biomarkers in pleural fluids.
The aim of this study was to compare and combine the 
diagnostic value for MPM of previously and newly identified sol-
uble markers. In a previous study, we identified the chemokine, 
chemokine (C-C motif) ligand 2 (CCL2), and galectin-3 
(LGALS3) as new, potential soluble markers for MPM diagno-
sis notably to differentiate MPM from lung adenocarcinoma.17 In 
the present study, levels of CCL2, galectin-3, SMRP, and secre-
tory leukocyte protease inhibitor (SLPI) in pleural effusions from 
patients with suspected MPM or ADCA were compared. In addi-
tion, the expression of these soluble markers was also determined 
in the supernatants of cell lines (17 MPM and  ADCA cell lines) 
that we established from pleural fluids. Individual- or combined-
expression analyses of all soluble markers were performed to 
determine their abilities to obtain an accurate diagnosis of MPM.
PATIENTS AND METHODS
Patients
Pleural-effusion samples from patients consulting for 
chest pain or shortness of breath with a suspicion of MPM, or 
with a recent diagnosis of MPM, were aseptically collected by 
thoracocentesis at the Laënnec Hospital (St.-Herblain, France) 
between 1998 and 2010. Samples were centrifuged at 1000 
g in a Heraeus Multifuge for 20 minutes at +4°C and super-
natants were aliquoted and stored at −80°C. Diagnoses were 
established by both fluid cytology and immunohistochemical 
staining of pleural biopsies performed by our pathology depart-
ment, Laënnec Hospital (St.-Herblain, France), then externally 
confirmed by Mesopath, the French panel of pathology experts 
for the diagnosis of mesothelioma, dividing the patients into 
three groups (Table 1): 61 patients with MPM, 25 patients with 
metastasis from ADCA, and 15 patients with benign pleural 
effusions (BPE). All recruited patients had received no prior 
anticancer therapy and gave signed, informed consent.
Enzyme-Linked Immunosorbent Assays
Pleural effusions were centrifuged and aliquots of pleural 
fluids were stored at −80°C until tested. Culture supernatants 
were collected as follows: 2 × 106 cells were plated by well in 
6-well plates. After 24 hours, three rinses were performed with 
complete, fetal calf serum (FCS)-free Roswell Park Memorial 
Institute 1640 medium. Two milliliters of complete Roswell 
Park Memorial Institute 1640 medium containing 2% FCS were 
added to each well and culture supernatants were collected 24 
hours later, centrifuged at 1000 g for 10 minutes, aliquoted and 
stored at −80°C. SMRP, SLPI, CCL2, and galectin-3 titrations 
were performed, respectively, with the MESoMARK immu-
noassay kit (CIS Bio International, Gif sur Yvette, France), 
the Human SLPI Assay Kit Quantikine (R&D Systems), the 
Human MCP-1 enzyme-linked immunosorbent assay (ELISA) 
kit (PromoKine), and the Human Galectin-3 ELISA kit 
(PromoKine) following the manufacturers’ recommendations.
Statistical Analysis
Comparisons of each population distribution were carried 
out using the nonparametric Kruskal–Wallis test followed by 
the Dunn’s post test. Biomarkers yielding p values<0.05 in the 
univariate analyses were entered into a multiple logistic regres-
sion model. The final model included the biomarkers indepen-
dently associated with the presence of MPM. Performances of 
the models were assessed by the Hosmer−Lemeshow statisti-
cal test and the measurement of the areas under receiver oper-
ating characteristic (RoC) curves. The best theoretical cutoffs 
were calculated by minimizing the distance between the point 
with specificity = 1 and sensitivity = 1 and the points on the 
RoC curves. Analyses were performed with R statistical 
software and GraphPad Prism (Prism 5 for Windows).
RESULTS
Determination of SMRP and SLPI Levels in 
Pleural Fluids
According to cytological and histological diagnoses, we 
established a collection of 61 pleural fluid samples from patients 
with MPM (49 epitheloid mesothelioma [EM], four mixed 
mesothelioma [MM], four sarcomatoid mesothelioma [SM] 
and four unspecified), 25 samples from patients with ADCA 
metastasis and 15 samples from patients with BPE (Table 1). 
We initially measured SMRP levels in pleural fluids by ELISA. 
As shown in Figure 1A, SMRP was present at higher levels in 
pleural effusions from patients with MPM (median, 33.80 nM) 
than those from patients with ADCA metastasis (median, 3.40 
nM) or BPE (median, 2.50 nM), with p < 0.001 for all com-
parisons. Areas under RoC were 0.902 ± 0.032 and 0.912 ± 
0.035 to differentiate MPM from ADCA and MPM from BPE, 
respectively (Table 2). Specificities and sensitivities obtained 
were 81.97% and 84.00% for a cutoff of 11.45 nM to differen-
tiate MPM from ADCA, and 75.41% and 93.33% with a cutoff 
of 14.60 nM to differentiate MPM from BPE (Table 3).
In a previous study,17 we identified SLPI as a potential 
marker for MPM. To evaluate the MPM diagnostic value of 
SLPI, we measured its level in our collection of pleural fluids 
using ELISA. SLPI concentrations were higher in pleural flu-
ids from patients with MPM (median, 228.20 ng/ml) than those 
with ADCA (median, 101.50 ng/ml) or BPE (median, 91.10 
ng/ml) (Fig. 1B). The areas under RoC curves were 0.730 ± 
0.054 and 0.706 ± 0.070 to differentiate MPM from ADCA 
and BPE, respectively (Table 2). A specificity of 70.49% and 
a sensitivity of 80.00% were obtained to differentiate MPM 
TABLE 1. Description of Groups and Demographic 
Characteristics of Recruited Patients
BPE MPM ADCA
Description 15 49 epithelioid
4 mixed
4 sarcomatoid
4 unspecified
10 lung
9 others
6 unspecified
Age, y  
(mean ± SD)
68.0 ± 15.7 67.4 ± 18.1 67.4 ± 17.9
Male sex, (%) 86.6 83.6 32.0
Confirmed asbestos 
exposure (%)
26.6 44.2 16.0
BPE, benign pleural effusion; MPM, malignant pleural mesothelioma; ADCA, 
adenocarcinoma.
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from ADCA or BPE, with cutoffs of 168.20 ng/ml and 163.60 
ng/ml, respectively (Table 3).
A major limit for the use of SMRP in diagnosing MPM 
is the lack of sensitivity of this marker, and especially in the 
nondetection of the sarcomatoid histological subtype. To 
determine whether our new soluble markers could improve 
MPM diagnosis, we analyzed the expression of CCL2, galec-
tin-3, and SLPI in each subtype of cancer (Fig. 2). Pleural fluid 
SMRP, CCL2, and galectin-3 levels differed among patients 
with mesothelioma (epithelioid [EM], sarcomatoid [SM], 
and mixed [MM] subtypes), ADCA (lung and other origins), 
and BPE (p < 0.0001). The difference in SLPI levels among 
subgroups of patients was also found to be significant, but to 
a lesser extent (p = 0.0052). SMRP levels were significantly 
higher in EM (median: 48.30 nM) than in ADCA (pulmonary 
ADCA median, 2.80 nM and other ADCA median, 3.40 nM) 
and BPE patients (median, 2.50 nM) (Fig. 2A). Whereas SMRP 
levels seemed to be higher in EM patients than in SM and 
MM subgroups, no statistically significant variation between 
these subgroups of MPM patients was observed. CCL2 lev-
els were significantly higher in EM and, interestingly, in SM 
patients (median, 2.82 ng/ml and 16.73 ng/l, respectively) 
than in other ADCA patients (median, 0.80 ng/ml). CCL2 lev-
els were also higher in EM (median, 16.73 ng/ml) than BPE 
patients (median, 1.47 ng/ml) (Fig. 2B). By contrast, pulmo-
nary ADCA patients presented significantly higher levels of 
galectin-3 (median, 67.33 ng/ml) in pleural fluids than did all 
subtypes of MPM (EM median, 11.10 ng/ml, p < 0.0001; SM 
median, 11.65 ng/ml, p < 0.05; and MM median, 8.79 ng/ml, 
p < 0.05) (Fig. 2C). No significant differences in the level of 
SLPI were observed among all patient subgroups (Fig. 2D).
Measurement of Soluble Markers in  
Cell-Culture Supernatants
over several years we have developed a collection 
of MPM and ADCA cell lines established from pleural flu-
ids of patients. Using this collection, we performed a tran-
scriptomic study to compare MPM and ADCA cell lines, 
allowing the identification of new soluble markers.17 To con-
firm these results, we measured the expression of CCL2, 
galectin-3, SLPI, and SMRP in cell-culture supernatants by ELISA 
(Fig. 3). SMRP secretion was higher in MPM than in ADCA 
cell-culture supernatants (22.54 nM/106 cells/24 hours and 10.68 
nM/106 cells/24 hours [median values], respectively) (Fig. 3A). 
Likewise, CCL2 levels were higher in the supernatants of MPM 
than in ADCA cell cultures (13.03 ng/ml/106 cells/24 hours and 
FIGURE 1. Measurements and diagnostic value of soluble mesothelin-related peptides (SMRP) and secretory leukocyte  
peptidase inhibitor (SLPI) in pleural fluids of patients. Pleural fluid SMRP (A) and SLPI (B) values in malignant pleural  
mesothelioma patients compared with adenocarcinoma and benign pleural effusion patients. Horizontal lines, median values.  
*p < 0.05, **p < 0.01, ***p < 0.001.
TABLE 2. ROC Curve Data for Ability of SMRP and SLPI to 
Differentiate MPM from ADCA or BPE
Marker AUC
95% Confidence 
Interval SE p
SMRP MPM  
vs. ADCA
0.902 0.8385–0.9655 0.03239 <0.0001
SMRP MPM  
vs. BPE
0.912 0.8433–0.9818 0.03533 <0.0001
SLPI MPM  
vs. ADCA
0.730 0.6250–0.8365 0.05395 0.0005
SLPI MPM vs. 
BPE
0.706 0.5670–0.8450 0,07090 0.013
RoC, receiver operating characteristic; SMRP, soluble mesothelin-related peptides; 
SLPI, secretory leukocyte peptidase inhibitor; BPE, benign pleural effusion; MPM, 
malignant pleural mesothelioma; ADCA, adenocarcinoma; AUC, area under the curve.
TABLE 3. Theoretical Best Cut-off Values to Differentiate 
MPM from ADCA or BPE
Marker Cutoff Specificity % Sensitivity %
SMRP MPM vs. ADCA 11.45 nM 81.97 84.00
SMRP MPM vs. BPE 14.60 nM 75.41 93.33
SLPI MPM vs. ADCA 168.20 ng/ml 70.49 80.00
SLPI MPM vs. BPE 163.60 ng/ml 70.49 80.00
MPM, malignant pleural mesothelioma; ADCA, adenocarcinoma; BPE, benign 
pleural effusion; SMRP, soluble mesothelin-related peptides; SLPI, secretory leukocyte 
peptidase inhibitor.
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2.41 ng/ml/106 cells/24 hours (median values), respectively) 
(Fig. 3B). Conversely, ADCA cells secreted higher levels of 
galectin-3 than did MPM cells (4.20 ng/ml/106 cells/24 hours 
and 1.87 ng/ml/106 cells/24 hours [median values], respectively) 
(Fig. 3C). Finally, SLPI levels were higher in MPM than in 
ADCA cell-culture supernatants (1114 pg/ml/106 cells/24 hours 
and 39.27 pg/ml/106 cells/24 hours [median values], respectively) 
(Fig. 3D). However, because of the spread of the values and the 
number of ADCA cell lines analyzed, the results observed were 
not statistically significant using the Mann-Whitney test.
Diagnostic Value of SMRP, SLPI, CCL2, and 
Galectin-3, Alone or in Combination
Figure 4A shows that SMRP remains the best 
soluble marker to differentiate MPM from ADCA and 
BPE (area under the curve [AUC] = 0.9059 ± 0.0283), 
as compared with CCL2 (AUC = 0.7912 ± 0.0454), 
galectin-3 (AUC = 0.7584 ± 0.0475), and SLPI (AUC = 
0.7219 ± 0.0516) (Table 4). The specificity and sensitiv-
ity for SMRP to differentiate MPM from ADCA and BPE 
were 63.93% and 100.00%, respectively, for a cutoff of 
24.05 nM (Table 5). Specificities and sensitivities were 80.33% 
and 72.50% with a cutoff of 1.61 ng/ml for CCL2, 67.21% 
and 82.50% with a cutoff of 14.60 ng/ml for LGALS3, and 
70.49% and 80.00% with a cutoff of 168.20 ng/ml for SLPI 
(Table 5). of interest, the SMRP/CCL2/galectin-3 marker 
combination reached an AUC of 0.968 (Fig. 4B) (Table 4).
DISCUSSION
MPM is a highly aggressive tumor associated with long-
term asbestos exposure. The main challenge for this disease 
is its early and specific diagnosis. Accurate identification of 
MPM should improve the medical care of patients. Soluble 
markers seem to be interesting tools for rapid MPM diagnosis 
and for monitoring treatment response. In a previous study, 
FIGURE 2. Pleural fluid levels of SMRP, CCL2, galectin-3, and SLPI in the subgroups studied. Pleural fluid SMRP (A), CCL2 (B), galec-
tin-3 (C), and SLPI (D) values in patients with epithelioid MPM (EM), sarcomatoid MPM (SM), mixed MPM (MM), pulmonary adenocar-
cinoma, other ADCA (ovarian, breast and unspecified) and BPE. *p < 0.05, **p < 0.01, ***p < 0.001. SMRP, soluble mesothelin-related 
peptides; SLPI, secretory leukocyte peptidase inhibitor; MPM, malignant pleural mesothelioma; EM, epithelioid mesothelioma; SM, 
sarcomatoid mesothelioma; MM, mixed mesothelioma; ADCA, adenocarcinoma; BPE, benign pleural effusion.
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FIGURE 3.  Measurements of SMRP, CCL2, galectin-3, and SLPI in cell culture supernatants. Culture supernatant SMRP  
(A), CCL2 (B), galectin-3 (C), and SLPI (D) values in MPM cells compared with ADCA cells. Horizontal lines, median values. 
SMRP, soluble mesothelin-related peptides; SLPI, secretory leukocyte peptidase inhibitor; MPM, malignant pleural  
mesothelioma; ADCA, adenocarcinoma.
FIGURE 4. Diagnostic values of SMRP, SLPI, CCL2, and galectin-3, alone or in combination. (A) ROC curve for SMRP (red), SLPI 
(green), CCL2 (black) or galectin-3 (blue) to distinguish between patients with MPM and patients with ADCA or BPE. (B) ROC 
curve for the combination SMRP, CCL2, and galectin-3 to distinguish between patients with MPM and patients with ADCA or 
BPE. SMRP, soluble mesothelin-related peptides; SLPI, secretory leukocyte peptidase inhibitor; ROC, receiver operating charac-
teristic; MPM, malignant pleural mesothelioma; ADCA, adenocarcinoma; BPE, benign pleural effusion.
we performed a transcriptomic study to compare MPM and 
pulmonary ADCA cell lines established from pleural fluids of 
patients.17 From this work, we identified CCL2 and galectin-3 
as new soluble markers to differentiate MPM from ADCA or 
BPE. We also found that SLPI mRNA was overexpressed in 
MPM cells. In this study, using commercially available ELISA 
assays we evaluated the levels of these biomarkers in pleu-
ral fluids collected over a 10-year period from patients with 
suspected MPM. As previously reported,12,13 we found that 
in addition to SMRP, CCL2, galectin-3, and SLPI are good 
markers for differentiating MPM from ADCA and BPE in 
pleural fluids. Moreover, we have determined that an analytic 
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combination of SMRP, CCL2, and galectin-3 improves the dif-
ferential diagnosis of MPM up to an AUC of 0.968, whereas 
SMRP alone is, in our use, 0.9059. This value is slightly higher 
than those reported by others, but in the same range.12,13,18,19
As previously observed, SMRP levels were higher 
in pleural fluids from patients with EM than in those from 
patients with SM or MM, ADCA or BPE.12 The nondetection 
of SM by SMRP represented the main limitation of this mark-
er.12 Several attempts were made to improve MPM diagnosis 
by combining SMRP with biomarkers used for the diagnosis 
of other cancers, such as cytokeratin fragment, carcinoembry-
onic antigen, carbohydrate antigen 15-3, carbohydrate 125, 
and osteopontin. However, all of these combinations showed 
poor, or no, benefit compared with the biomarker alone.20 We 
showed previously that chemokine CCL2 levels were higher in 
patients with MPM, whatever the subtype. However, when we 
performed a more detailed evaluation of the ADCA group, we 
found that the ability of CCL2 to discriminate MPM from pul-
monary ADCA was not as good as expected. This suggested 
that a combination of SMRP and CCL2 allows the detection 
of MPM, including SM. However, this combination does not 
clearly distinguish MPM from pulmonary ADCA, which is 
unsatisfying for the diagnosis of MPM. Thus, the high lev-
els of galectin-3 measured in the pleural fluids of pulmonary 
ADCA patients as compared with those of MPM and its sub-
groups justified its association with SMRP and CCL2. SLPI 
is an alarm antiprotease overexpressed in ovarian-cancer cells 
and associated with the promotion of malignancy.21,22 Pleural 
fluid levels of SLPI were mainly elevated in epithelioid MPM 
patients, whereas SLPI levels were elevated in the other MPM 
subtypes, and the ADCA and BPE groups were similar, as 
observed for SMRP.
The results obtained from the experiments conducted 
with pleural liquids were reinforced by the analysis of cul-
ture supernatants from MPM and ADCA cell lines estab-
lished from pleural fluids.17 MPM cell lines produced higher 
levels of SMRP, CCL2, and SLPI than did ADCA cell lines. 
Conversely, ADCA cell lines produced higher levels of galec-
tin-3 than did MPM cell lines. These data were in parallel with 
biomarker determinations in pleural fluids and confirmed their 
specificities.
The complementarities of these biomarkers were stud-
ied using multiple logistic regressions that showed CCL2 
(p = 0.002), LGALS3 (p = 0.035), and SMRP (p = 0.001) 
as statistically significant biomarkers, whereas SLPI was not 
significant (p = 0.28) when adjusted with the other biomark-
ers, demonstrating its correlation with the other biomark-
ers. Moreover, RoC curve analysis using the combination 
SMRP/galectin-3/CCL2 (AUC = 0.968) showed an interest-
ing improvement in MPM diagnosis as compared with SMRP 
alone (AUC = 0.9059). Using the SMRP/CCL2/galectin-3 
combination to classify the pleural fluids, according to their 
best cutoff values, only seven of 106 samples were misclas-
sified (one false positive and six false negatives). In all cases 
of false negatives, the reason for the misclassification of the 
sample was a high galectin-3 level. In two cases, the diagno-
ses were ambiguous and for two others, atypical cells were 
observed in the pleural fluid cytological examination. The 
false-positive sample was from a patient with rheumatoid 
polyarthritis presenting a bilateral pleurisy characterized by 
low levels of SMRP and galectin-3, and a high level of CCL2, 
probably resulting from his pathology.23 Despite the existence 
of limits represented by these seven samples, the SMRP/
CCL2/galectin-3 combination could clearly improve the diag-
nosis of MPM on the basis of the determination of their levels 
in pleural fluids. This combination should now be evaluated 
in multicenter studies to validate its potential utility for MPM 
diagnosis.
The determination of these new biomarkers in serum 
samples also represents an interesting option that avoids 
recourse to an invasive procedure, such as thoracoscopy. 
SMRP measurements in serum samples have previously been 
performed and shown diagnostic performance similar to those 
in pleural fluids.12,13,24 Thus, at the least, CCL2 and galectin-3 
determinations should be carried out on serum samples to 
evaluate their diagnostic value. As for SMRP, the correlation 
of CCL2 and galectin-3 levels in pleural fluids and in blood 
samples should be studied to determine whether these data are 
correlated or complementary.
ACKNOWLEDGMENTS
This work was supported by INSERM and grants 
from la Ligue Interrégionale Contre le Cancer (Comités 
Départementaux du Grand Ouest: CD85, CD49, CD72, CD56 
and CD79), la Fondation de l’Avenir, la Fondation pour la 
Recherche Médicale, l’Association ARSMeso44 and la Région 
Pays de la Loire (Cancéropôle Grand Ouest).
TABLE 5. Best Cut-Off Values to Differentiate MPM from 
ADCA and BPE
Marker Cut-off Specificity % Sensitivity %
SMRP 24.05 nM 63.93 100.00
CCL2 1.61 ng/ml 80.33 72.50
LGALS3 14.60 ng/ml 67.21 82.50
SLPI 168.20 ng/ml 70.49 80.00
MPM, malignant pleural mesothelioma; ADCA, adenocarcinoma; BPE, benign 
pleural diseases; SMRP, soluble mesothelin-related peptides; LGALS3, galectin-3; 
SLPI, secretory leukocyte peptidase inhibitor.
TABLE 4. ROC Curve Data for Ability of Biomarkers to 
Differentiate MPM from ADCA and BPE
Marker AUC
95% confidence 
interval SE p
SMRP 0.9059 0.8503–0.9616 0.02838 <0.0001
CCL2 0.7912 0.7020–0.8803 0.04547 <0.0001
LGALS3 0.7584 0.6652–0.8516 0.04752 <0.0001
SLPI 0.7219 0.6207–0.8231 0.05161 <0.001
SMRP,CCL2 
and LGALS3
0.9680 0.9120–0.9930 0.0168 <0.0001
RoC, receiver operating characteristic; MPM, malignant pleural mesothelioma; 
ADCA, adenocarcinoma; BPE, benign pleural effusion; SMRP, soluble mesothelin-
related peptides; LGALS3, galectin-3; SLPI, secretory leukocyte peptidase inhibitor.
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